Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.

The global prurigo nodularis market is surging due to rising prevalence, increased awareness, and treatment innovations. Key drivers include advanced biologic therapies like dupilumab, addressing ...

EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha The ...

A dermatologist discusses nemolizumab (Nemluvio). Get the facts on this new treatment for prurigo nodularis: how well it works and who might benefit.

Prurigo nodularis is an extremely itchy skin condition. It causes a rash that often includes hard lumps called nodules. You might also hear it called nodular prurigo. Doctors don’t know exactly ...

The Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab-ilto) for the treatment of adults with prurigo nodularis.

The US Food and Drug Administration (FDA) has approved Galderma’s monoclonal antibody Nemluvio (nemolizumab) to treat adults with prurigo nodularis. Estimated to affect up to 181,000 people in the US, ...

(HealthDay News) — For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1 inhibitor, is effective and well tolerated, according to ...

TUESDAY, June 25, 2024 (HealthDay News) -- For patients with prurigo nodularis (PN) and chronic pruritus of unknown origin (CPUO), abrocitinib, a Janus kinase 1 inhibitor, is effective and well ...

A large international cohort study identified a higher risk for cardiovascular diseases and mortality in patients with prurigo nodularis (PN), particularly among women and White patients. Studies ...